|
Corporate Governance Advisor by Broc Romanek |
|
Media:Price Per Unit:
$473
Call for Pricing |
PIN:SS10676171 Format:Paperback Pub. Cycle:6 Issues per year More Info: 888-224-7377 |
|
Each issue of the Corporate Governance Advisor analyzes the hottest issues and developments thoroughly to arm you with the information you need to protect your company or client more effectively.
With the Corporate Governance Advisor, you will always be prepared to deal swiftly and effectively with the critical and fast-changing rules and regulations of the Sarbanes-Oxley Act, the PCAOB, and other statutory and litigation issues. Stay aware of the critical developments that can have significant impact or your company’s and client’s needs. Every other month, the Corporate Governance Advisor gathers the timeliest information directly from the practicing professionals on the forefront of the industry.
Highlights of important recent issues include:
These are just some of the many issues being raised in a broad-ranging reexamination that is being conducted throughout this country under the general banner of corporate governance. Published six times a year, The Corporate Governance Advisor addresses these questions and many others. It provides up-to-date, insightful coverage of corporate governance issues, with thought-provoking analysis and timely news reporting. The Corporate Governance Advisor monitors developments in Congress, the state legislatures, the SEC, the state securities regulators, other regulatory agencies, and securities exchanges with the assistance of Institutional Shareholder Services (ISS) in Bethesda, MD.
SEC Deputy Director Shelley Parratt urged companies not to wait for staff comments to improve their compensation discussion and analysis ("CD&A"). After three years of comments on how to improve their disclosure, Parratt said companies now should be prepared to amend their filings if they do not materially comply with the rules.
Insights into legislative activity, cases of note, and other breaking news.
Insights and commentary on health reform.
A forum to discuss antitrust and trade regulation law.
Commentary and musings about securities regulation.